Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0QQSDO
ADC Name
SGN-PDL1V
Synonyms
PF-08046054; SGN PDL1V; SGN-PDL1V; SGNPDL1V
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Phase 3
Indication
In total 7 Indication(s)
Lung cancer
Phase 3
Clinical Trial
Breast cancer
Phase 1
Clinical Trial
Gastric cancer
Phase 1
Clinical Trial
Head and neck cancer
Phase 1
Clinical Trial
Melanoma
Phase 1
Clinical Trial
Oesophageal cancer
Phase 1
Clinical Trial
Ovarian cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Humanized Anti-PD-L1 SGN-PDL1V mAb
  Antibody Info 
Antigen Name
Programmed cell death 1 ligand 1 (CD274)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
vedotin
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05208762
Phase 1
A phase 1 study of SGN-PDL1V in advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05208762  Clinical Status Phase 1
Clinical Description A phase 1 study of SGN-PDL1V in advanced solid tumors.
References
Ref 1 A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors